Enterotoxigenic Escherichia coli antigens (Lipopolysaccharide, CFA-I, and Flagellin) (ETEC Antigens)

This target profile represents a composite of major surface antigens from Enterotoxigenic Escherichia coli (ETEC), the primary cause of traveler's diarrhea and a significant cause of morbidity in children in low-income countries. Lipopolysaccharide (LPS) is a major component of the Gram-negative outer membrane that triggers innate immune responses via TLR4; CFA-I (Colonization Factor Antigen I) is a fimbrial adhesin critical for bacterial attachment to the intestinal epithelium; and Flagellin is the protein subunit of the flagellum responsible for bacterial motility and TLR5 activation. In the context of drug and vaccine development, these molecules are targeted to elicit a robust mucosal immune response, primarily through the production of secretory IgA antibodies that block bacterial colonization and neutralize the pathogen before it can release enterotoxins. Therapeutic strategies include oral whole-cell inactivated vaccines (like ETVAX) and subunit vaccines that combine these antigens to provide broad protection against various ETEC serotypes. Understanding the interplay between these antigens is crucial for developing effective immunotherapies against enteric infections.

Other names

LPSColonization Factor Antigen IFliCBacterial flagellinEndotoxinETEC surface antigens

Vaccines targeting these components induce secretory IgA and systemic IgG antibodies that neutralize bacterial adhesion (CFA-I), inhibit motility (Flagellin), and provide O-antigen specific immunity (LPS) to prevent colonization and infection by Enterotoxigenic Escherichia coli.